Analytical Profiling of Eliglustat for Gaucher Disease: Method Development and Validation
Analytical Profiling of Eliglustat for Gaucher Disease: Method Development and Validation
This review paper comprehensively investigates the analytical profiling of eliglustat, an inhibitor for Gaucher disease. Methodologies employing High-Performance Liquid Chromatography (HPLC), 2D Nuclear Magnetic Resonance (2DNMR), and High-Resolution Mass Spectrometry (HRMS) are explored to elucidate the pharmacodynamic and pharmacokinetic properties of eliglustat. Additionally, it delves into the chemistry, solubility, and mechanism of action of eliglustat. Through a meticulous examination of the available data, this review aims to provide a comprehensive understanding of eliglustat's efficacy and safety profile for the treatment of Gaucher disease. More than 150 papers from eminent institutions doing scientific, technological, and medical research are currently available. The current review effectively outlines the conventional, hyphenated, and distinctive approaches to SFV (structural fingerprinting of variants).
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!